EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis

Samuel A Fisch, Eitan J Neugut, Nicole Cornet, Daniela Quigee, Alfred I Neugut, Daniel E Freedberg

Frontiers in Pharmacology · 29.09.2026 · 17

DOI: 10.3389/fphar.2026.1936967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.09.2026. Verfasst von Samuel A Fisch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

By 2021, regulatory agencies had approved two glucagon-like peptide-1 receptor agonists (GLP-1RAs), semaglutide and liraglutide, for the treatment of type 2 diabetes and obesity. Since then, concerns have emerged about whether adverse events (AEs) differ by GLP-1RA or indication. Research design and methods We analyzed the Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2021–2025) to compare adverse events associated with semaglutide and liraglutide indications. Comparisons with metformin and orlistat helped distinguish drug-related signals from disease-related signals. We defined safety signals by a positive reporting odds ratio and at least one other positive disproportionality metric.

Results

Among 8,213,105 FAERS reports, 33,259 met the inclusion criteria. Semaglutide generated more reports for type 2 diabetes than for obesity (13,168 vs. 5,444), and liraglutide showed a similar pattern (1,201 vs. 837). GLP-1RAs exhibited gastrointestinal AEs. Semaglutide showed signals for slowed gastrointestinal motility across both indications, particularly impaired gastric emptying, in both type 2 diabetes and obesity reports (ROR = 8.35, 95% CI = 1.16–59.97 and ROR = 4.01, 95% CI = 2.12–7.58, respectively). Liraglutide demonstrated signals for more severe gastrointestinal AEs, including abdominal distention in type 2 diabetes (ROR = 1.46, 95% CI = 1.12–1.91) and pancreatitis in obesity (ROR = 2.90, 95% CI = 1.91–4.39) reports. Additional notable safety signals included optic ischemic neuropathy with semaglutide (ROR = 4.42, 95% CI = 1.41–13.87) and psychiatric AEs, including suicidal ideation (ROR = 5.98, 95% CI = 1.24–24.19).

Conclusion

We identified robust signals for GLP-1RAs, including impaired gastric emptying, ileus, and ischemic optic neuropathy. Additionally, we identified signals for suicidal ideation. Future studies are needed to evaluate for causal relationships.

Schlagwörter

Stichwörter der Autor:innen

FDA Adverse Event Reporting Systemdisproportionality analysisglucagon-like peptide-1glucagon-like peptide-1 receptor agonistsliraglutidesemaglutide

Autor:innen und Institutionen

  • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States.
  • Department of Statistics, Columbia University, New York, NY, United States.
  • Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, United States.

Zitieren

APA

Fisch, S. A., Neugut, E. J., Cornet, N., Quigee, D., Neugut, A. I., & Freedberg, D. E. (2026). Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1936967

Vancouver

Fisch SA, Neugut EJ, Cornet N, Quigee D, Neugut AI, Freedberg DE. Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1936967

BibTeX
@article{Fisch2026,
  author = {Fisch, Samuel A and Neugut, Eitan J and Cornet, Nicole and Quigee, Daniela and Neugut, Alfred I and Freedberg, Daniel E},
  title = {Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1936967}
}
Kostenlos starten →